HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,

Slides:



Advertisements
Similar presentations
The results of the Study of Heart and Renal Protection (SHARP)
Advertisements

SHARP trial Study of Heart and Renal Protection : a randomised placebo-controlled trial The e ff ects of lowering LDL cholesterol with simvastatin plus.
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
The results of the Study of Heart and Renal Protection (SHARP) Colin Baigent, Martin Landray on behalf of the SHARP Investigators Disclosure: SHARP was.
HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. Jane Armitage.
HPS2-THRIVE: Treatment of HDL to Reduce the Incidence of Vascular Events Jane Armitage on behalf of the THRIVE Collaborative Group Financial Disclosure:
HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. Jane Armitage.
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Cholesterol quintile (mg/dL)
Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.
IHS SDPI COMPETITIVE GRANT PROGRAM CVD RISK REDUCTION DEMONSTRATION PROJECT WHAT IS THE EVIDENCE? HOW ARE WE DOING? HOW CAN WE DO BETTER? Karl Hammermeister,
Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK.
Lancet : doi: /S (08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.
Women’s Health Study: Vitamin E in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Julie E. Buring.
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
(N=488) Simvastatin in Patients With Prior Cerebrovascular Disease: HPS *29% RRR, p=0.001 Heart Protection Study Collaborative Group. Lancet. 2004;363:
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Slide Source: Lipids Online Slide Library Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.
VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.
Plasma Homocysteine and Coronary Heart Disease David S. Rosenblatt, MD Department of Human Genetics McGill University.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.
Scandinavian Simvastatin Survival Study (4S) The Lancet, Vol 344, November 19, 1994.
ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
VBWG PROactive: Study design Dormandy JA et al. Lancet. 2005;366: Charbonnel B et al. Diabetes Care. 2004;27: Objective: Assess the effects.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
ASCOT and Steno-2: Aggressive risk reduction benefits two different patient populations *Composite of CV death, nonfatal MI or stroke, revascularization,
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
4S: Scandinavian Simvastatin Survival Study
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.
ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.
Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:
Baseline characteristics and eligibility criteria of participating trials Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:
Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial
Title slide.
HOPE: Heart Outcomes Prevention Evaluation study
Pravastatin in Elderly Individuals at Risk of Vascular Disease
ELIGIBILITY: MRC/BHF Heart Protection Study
AIM HIGH Niacin plus Statin to prevent vascular events
First time a CETP inhibitor shows reduction of serious CV events
Scandinavian Simvastatin Survival Study (4S)
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
The results of the SHARP trial
Cause of death Treatment-arm events, % (n=45 054)
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.
The results of the SHARP trial
PROSPER: trial design                                                                                                                                                                 
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
FIELD: Primary outcome
Presentation transcript:

HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease, but all at high risk, and with a broad range of baseline cholesterol levels Reference HPS Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.

HPS: Heart Protection Study - TRIAL DESIGN - Design Multicenter, randomized, double-blind, placebo-controlled Patients 20,536 patients aged 40–80 years, with and without coronary heart disease, but all at high risk, and with broad range of baseline total cholesterol: all >135mg/dL (>3.5mmol/L), mean 230 mg/dL (5.9 mmol/L) Follow up and primary endpoint Primary endpoint: all-cause mortality. Mean 5 years follow up. Treatment Placebo or simvastatin 40 mg daily

HPS: Heart Protection Study - TRIAL DESIGN continued- All patients Men Women History of coronary disease Previous MI Other Other risk factors in absence of coronary disease a Baseline characteristics 20,536 15, No Cerebrovascular disease Peripheral arterial disease Diabetes mellitus % of total a Some patients had more than one of these conditions. HPS Collaborative Group.Lancet 2002;360:7Ð22.

HPS: Heart Protection Study - RESULTS - All-cause mortality in simvastatin group significantly reduced compared with placebo (12.9 vs. 14.7%, P<0.0003); reduction was attributed largely to significant reduction in coronary death: —Other vascular death reduced but with marginal significance —Nonvascular death reduced but not significantly First major vascular event rate significantly reduced, as were the individual event rates (fatal/nonfatal MI, fatal/nonfatal stroke, and revascularization) No difference in new cancers (7.9 vs 7.8%, rate ratio 1.0, P=0.9) except nonmelanoma skin cancer (2.4 vs 2.0%) No difference in withdrawal due to myopathy (0.5% in both groups)

HPS: Heart Protection Study - RESULTS continued - Vascular causes Coronary Other vascular Subtotal: any vascular Non-vascular causes Neoplastic Respiratory Other medical Nonmedical Subtotal: any nonvascular ANY DEATH (5.7) (1.9) (7.6) (3.5) (0.9) (0.8) (0.2) (5.3) (12.9) Cause of death Death rate ratio (95% CI)Simvastatin (n=10,269) No.(%) (6.9) (2.2) (9.1) (3.4) (1.1) (0.9) (0.2) (5.6) (14.7) RR=0.83 (0.75–0.91) P< RR=0.95(0.85–1.07) P=0.4 RR=0.87(0.81–0.94) P< No.(%) Placebo (n=10,267) HPS Collaborative Group. Lancet 2002;360:7–22. Dashed line indicates overall RR for a subtotal Simvastatin betterPlacebo better Cause-specific mortality

HPS: Heart Protection Study - RESULTS continued - P Nonfatal MI or coronary death0.73 (0.67–0. 79)< First major vascular event 898 No. (8.7) (%) Simvastatin (n=10,269) 1212 No. (11.8) Fatal or nonfatal stroke0.75 (0.66–0.85)< (4.3)585(5.7) Revascularization0.76 (0.70–0.83)< (9.1)1205(11.7) Any major vascular event a 0.76 (0.72–0.81)< (19.8)2585(25.2) (%) Placebo (n=10,267) Event rate ratio (95% CI) HPS Collaborative Group. Lancet 2002;360:7–22. a Data are for patients having first event of each type, hence non-additivity

HPS: Heart Protection Study - SUMMARY - In high-risk patients with a broad range of baseline cholesterol values, simvastatin reduced: All-cause mortality Coronary deaths Major vascular events